XML 15 R4.htm IDEA: XBRL DOCUMENT v3.20.2
Condensed Consolidated Statements of (Loss) Income (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 9 Months Ended
Jun. 26, 2020
Jun. 28, 2019
Jun. 26, 2020
Jun. 28, 2019
Income Statement [Abstract]        
Revenue $ 2,152,253 $ 4,010,761 $ 10,137,409 $ 12,276,097
Costs and Expenses:        
Cost of services provided 2,265,614 3,594,978 9,441,316 11,029,382
Depreciation and amortization 148,060 148,779 443,971 447,408
Goodwill impairment and asset write-downs     198,600 0
Selling and general corporate expenses 66,176 78,185 224,502 270,600
Gain on sale of Healthcare Technologies     0 (156,309)
Costs and Expenses 2,479,850 3,821,942 10,308,389 11,591,081
Operating (loss) income (327,597) 188,819 (170,980) 685,016
Interest and Other Financing Costs, net 94,235 82,220 273,642 249,375
(Loss) Income Before Income Taxes (421,832) 106,599 (444,622) 435,641
(Benefit) Provision for Income Taxes (165,524) 23,535 (132,176) 72,589
Net (loss) income (256,308) 83,064 (312,446) 363,052
Less: Net income attributable to noncontrolling interest 132 109 493 60
Net (loss) income attributable to Aramark stockholders $ (256,440) $ 82,955 $ (312,939) $ 362,992
(Loss) Earnings per share attributable to Aramark stockholders:        
Basic (in dollars per share) $ (1.01) $ 0.34 $ (1.25) $ 1.47
Diluted (in dollars per share) $ (1.01) $ 0.33 $ (1.25) $ 1.44
Weighted Average Shares Outstanding:        
Basic (in shares) 252,943 246,928 251,343 246,665
Diluted (in shares) 252,943 251,147 251,343 251,271